title: Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.
abstract: Bacillus anthracis, the bacterium that causes anthrax, is an agent of bioterrorism. The most effective antimicrobial therapy for B. anthracis infections is unknown. An in vitro pharmacodynamic model of B. anthracis was used to compare the efficacies of simulated clinically prescribed regimens of moxifloxacin, linezolid, and meropenem with the "gold standards," doxycycline and ciprofloxacin. Treatment outcomes for isogenic spore-forming and non-spore-forming strains of B. anthracis were compared. Against spore-forming B. anthracis, ciprofloxacin, moxifloxacin, linezolid, and meropenem reduced the B. anthracis population by 4 log(10) CFU/ml over 10 days. Doxycycline reduced the population of this B. anthracis strain by 5 log(10) CFU/ml (analysis of variance [ANOVA] P = 0.01 versus other drugs). Against an isogenic non-spore-forming strain, meropenem killed the vegetative B. anthracis the fastest, followed by moxifloxacin and ciprofloxacin and then doxycycline. Linezolid offered the lowest bacterial kill rate. Heat shock studies using the spore-producing B. anthracis strain showed that with moxifloxacin, ciprofloxacin, and meropenem therapies the total population was mostly spores, while the population was primarily vegetative bacteria with linezolid and doxycycline therapies. Spores have a profound impact on the rate and extent of killing of B. anthracis. Against spore-forming B. anthracis, the five antibiotics killed the total (spore and vegetative) bacterial population at similar rates (within 1 log(10) CFU/ml of each other). However, bactericidal antibiotics killed vegetative B. anthracis faster than bacteriostatic drugs. Since only vegetative-phase B. anthracis produces the toxins that may kill the infected host, the rate and mechanism of killing of an antibiotic may determine its overall in vivo efficacy. Further studies are needed to examine this important observation.
authors.affiliation: Ordway Research Institute, Center for Biodefense and Emerging Infections, Albany, New York, USA. arnold.louie@medicine.ufl.edu
authors.forename: Arnold
authors.initials: A
authors.lastname: Louie
authors.forename: Brian D
authors.initials: BD
authors.lastname: VanScoy
authors.forename: David L
authors.initials: DL
authors.lastname: Brown
authors.forename: Robert W
authors.initials: RW
authors.lastname: Kulawy
authors.forename: Henry S
authors.initials: HS
authors.lastname: Heine
authors.forename: George L
authors.initials: GL
authors.lastname: Drusano
mesh_terms: D000081:Acetamides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology; D001408:Bacillus anthracis / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D002939:Ciprofloxacin / Q000494:pharmacology; D004318:Doxycycline / Q000494:pharmacology; D024841:Fluoroquinolones; D000069349:Linezolid; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects; D008954:Models, Biological; D000077266:Moxifloxacin; D023303:Oxazolidinones / Q000494:pharmacology; D011237:Predictive Value of Tests; D011804:Quinolines / Q000494:pharmacology; D013171:Spores, Bacterial / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D013845:Thienamycins / Q000494:pharmacology; D019562:Viral Load / Q000187:drug effects*
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D023303:Oxazolidinones; D011804:Quinolines; D013845:Thienamycins; D002939:Ciprofloxacin; D000077731:Meropenem; D000069349:Linezolid; D004318:Doxycycline; D000077266:Moxifloxacin